Sandoz Group (OTCMKTS:SDZNY) Sees Unusually-High Trading Volume – Still a Buy?

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) shares saw strong trading volume on Wednesday . 65,426 shares changed hands during trading, an increase of 112% from the previous session’s volume of 30,842 shares.The stock last traded at $83.78 and had previously closed at $82.65.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on SDZNY shares. Jefferies Financial Group raised shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 12th. Royal Bank Of Canada cut shares of Sandoz Group from a “moderate buy” rating to a “hold” rating in a research note on Monday, March 23rd. The Goldman Sachs Group upgraded shares of Sandoz Group to a “strong-buy” rating in a research note on Wednesday, April 1st. Finally, Barclays upgraded shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Three analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Strong Buy”.

Sandoz Group Price Performance

The business’s 50-day moving average is $81.38 and its 200-day moving average is $77.78. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.77 and a current ratio of 1.18.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.